Attention-deficit hyperactivity disorder: Determination of the optimal medical treatment duration

Zhurnal Nevrologii i Psihiatrii imeni S.S. Korsakova

Volumn 111, Issue 10, 2011, Pages 28-32

  Zavadenko, N N ^a   Suvorinova, N Yu ^a  

^a NONE

Author keywords

Attention deficit hyperactivity disorder (ADHD); Pantogam; Pharmacotherapy; Psychosocial adaptation problems

Indexed keywords

4 AMINOBUTYRIC ACID; DRUG DERIVATIVE; HOPANTENATE CALCIUM; NOOTROPIC AGENT; PANTOTHENIC ACID;

ARTICLE; ATTENTION DEFICIT DISORDER; CHILD; DRUG ADMINISTRATION; FEMALE; HUMAN; MALE;

ATTENTION DEFICIT DISORDER WITH HYPERACTIVITY; CHILD; DRUG ADMINISTRATION SCHEDULE; FEMALE; GAMMA-AMINOBUTYRIC ACID; HUMANS; MALE; NOOTROPIC AGENTS; PANTOTHENIC ACID;

EID: 84860249349     PISSN: 19977298     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (5)

1. Diagnostic and Statistical Manual of Mental Disorders (4th edition Revision) (DSM-IV-TR), by the American Psychiatric Association 2000, Washington, DC.
2. DuPaul G.J., Power T.J., Anastopoulos A.D., Reid R. ADHD Rating Scale-IV: Checklists, Norms, and Clinical Interpretations. New York: Guilford 1998.
3. Hammerness P., McCarthy Mancuso E., Gendron C., Geller D. Atomoxetine for the treatment of attention-deficit/hyperactivity disorder in children and adolescents: a review. Neuropsychiatric Disease and Treatment 2009; 5: 215-226.
4. Prasad S., Harpin V., Poole L. et al. A multi-centre, randomised, open-label study of atomoxetine compared with standard current therapy in UK children and adolescents with attention-deficit/hyperactivity disorder (ADHD). Current Medical Research and Opinion 2007; 23: 379-394.
5. Weiss M.D., Wasdell M.B., Bomben M.M. Weiss functional impairment rating scale - parent report (WFIRS-P) 2004.